How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,610 results for

Anti-Retroviral Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Validity of reported retention in antiretroviral therapy after roll-out to peripheral facilities in Mozambique: Results of a retrospective national cohort analysis. Full Text available with Trip Pro

Validity of reported retention in antiretroviral therapy after roll-out to peripheral facilities in Mozambique: Results of a retrospective national cohort analysis. Retention in anti-retroviral therapy (ART) presents a challenge in sub-Saharan Africa. In Mozambique, after roll-out to peripheral facilities, the 12-month retention rate was reported mostly from sites with an electronic patient tracking system (EPTS), representing only 65% of patients. We conducted a nationally representative study

2018 PLoS ONE

62. Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1. Full Text available with Trip Pro

Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1. Although anti-retroviral therapies have greatly extended the lives of HIV infected individuals, current treatments are unable to completely eliminate virally infected cells. A number of latency reversing agents have been proposed for use in a "shock and kill" strategy to reactivate latent HIV, thus making it vulnerable to killing mechanisms. Procyanidin trimer C1 (PC1) is a flavonoid found

2018 PLoS ONE

63. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

not so identified.xiii Definition of key terms Serodiscordant couples are couples in which one partner is living with HIV and the other is HIV-negative. A couple refers to two people in an ongoing sexual relationship; each of these people is referred to as a partner in the relationship. How individuals define their relationships will vary according to their cultural and social context. Antiretroviral therapy ARV (antiretroviral) drugs refer to the medicines used to treat HIV. ART (antiretroviral (...) ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTIONCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SECOND EDITIONWHO Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – 2nd ed. 1.HIV Infections – drug therapy. 2.HIV Infections – prevention

2016 World Health Organisation HIV Guidelines

64. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

2015WHO Library Cataloguing-in-Publication Data Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 1.HIV Infections – drug therapy. 2.Anti-Retroviral Agents – administration and dosage. 3.Anti-Retroviral agents – therapeutic use. 4.Time-to-Treatment. 5.Guideline. I.World Health Organization. ISBN 978 92 4 150956 5 (NLM classification: WC 503.2) © World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available (...) to the medicines used to treat HIV. ART (antiretroviral therapy) refers to the use of a combination of three or more ARV drugs for treating HIV infection. ART involves lifelong treatment. Use of ARV drugs for HIV prevention refers to the HIV prevention benefits of ARV drugs and includes ARV drugs given to the mother or infant for preventing the mother-to-child transmission of HIV (PMTCT), ARV drugs to reduce the transmission of HIV among serodiscordant couples and ARV drugs to prevent people from acquiring HIV

2015 World Health Organisation HIV Guidelines

65. Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy

Observational Model: Other Time Perspective: Retrospective Official Title: Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy in The Region Of Madrid: A Population-Based, Cross-Sectional Study Estimated Study Start Date : June 2017 Estimated Primary Completion Date : October 2017 Estimated Study Completion Date : October 2017 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome (...) Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents

2017 Clinical Trials

66. Anthropometric Improvement among HIV Infected Pre-School Children Following Initiation of First Line Anti-Retroviral Therapy: Implications for Follow Up. Full Text available with Trip Pro

Anthropometric Improvement among HIV Infected Pre-School Children Following Initiation of First Line Anti-Retroviral Therapy: Implications for Follow Up. Antiretroviral therapy (ART) is a lifesaving intervention for HIV infected children. There is a scarcity of data on immunological recovery and its relation with growth indicators among HIV infected young children. The current study aims to assess the pattern of anthropometric Z-score improvement following initiation of first-line ART among

2016 PLoS ONE

67. The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug. (Abstract)

The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug. This study examines the effect of the addition of IMOD, a novel multi-herbal drug to the highly active anti-retroviral therapy (HAART) regimen, on the immunological status of HIV-positive patients.A randomized two-parallel-group (HAART group versus HAART+IMOD group), pretest-posttest design was used.Sixty patients with indications for treatment with the HAART regimen participated (...) . One week before and 2 days after the treatments, immunological parameters including total lymphocyte count (TLC) and CD4 cell count were assessed.The intervention group received the HAART regimen plus IMOD every day for 3 months. The control group received only the HAART regimen every day for 3 months.In the intervention group, a significant difference was observed in CD4between before and after drug therapy (CD4 was increased). However, in the control group, the difference in CD4

2019 Avicenna journal of phytomedicine Controlled trial quality: uncertain

68. Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. Full Text available with Trip Pro

Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. People who inject drugs (PWID) in Kazakhstan face many barriers to HIV testing as well as to accessing HIV care, to retention in HIV care, and to initiating and adhering to anti-retroviral treatment (ART). Needle and syringe programs (NSPs) are an opportune setting for integrated interventions to link PWID to HIV care.This Hybrid Type II study employs a stepped-wedge

2019 Implementation Science

69. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. Full Text available with Trip Pro

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial.Forty-two HIV-positive cases were matched to 220 HIV-negative (...) controls by age, gender, ethnicity, and trial site using coarsened exact matching. Grade 3 and 4 adverse events (AEs) were summarised by MedDRA System Organ Class. Kaplan-Meier curves for time to first grade 3 or 4 AE were constructed according to HIV status with hazard ratios calculated. Patients were considered cured if they were culture negative 18 months after commencing therapy with ≥2 consecutive negative culture results.Twenty of 42 (47.6%) HIV-positive and 34 of 220 (15.5%) HIV-negative

2019 BMC pulmonary medicine

70. Longitudinal changes in Spirometry in perinatally HIV-infected South African adolescents on antiretroviral therapy. (Abstract)

, the Cape Town Adolescent Anti-retroviral cohort (CTAAC).HIV-infected adolescents aged 9-14 years, with at least 6 months of HAART, and a comparator group of healthy HIV-uninfected, age-matched controls were enrolled in CTAAC. Spirometry and bronchodilator testing was done at baseline, 12 and 24 months. Mixed-effect models were used to compute longitudinal changes in lung function.Five hundred and fifteen HIV-infected adolescents, mean (SD) age, 12 (1.6) years, 50.4% male; and 110 HIV-uninfected (...) Longitudinal changes in Spirometry in perinatally HIV-infected South African adolescents on antiretroviral therapy. Despite increased access to highly active antiretroviral therapy (HAART), lung disease remains common in HIV-infected adolescents. There is limited information on changes in lung function over time in perinatally HIV-infected adolescents on HAART.To investigate the progression of spirometry findings over 2 years in HIV-infected adolescents on HAART in a prospective cohort

2019 Clinical Infectious Diseases

71. Mindfulness-based Therapy for people living with HIV

in people living with HIV. A recent RCT with 76 participants compared MBSR to participants on a wait list and found reduced frequency, severity and distress from symptoms resulting from anti-retroviral therapy (ARTs).(3) In addition, two small studies (one a RCT and one a pilot study) found that HIV positive participants receiving MBSR (2) or practicing mindfulness meditation (4) over the course of 8 weeks stabilized or increased their CD4 counts. Participants in the pilot study reported that group (...) and practice. Suggested Citation: Rapid Response Service. Rapid response: Rapid response: Mindfulness-based Therapies. Toronto, ON: Ontario HIV Treatment Network; May 2012. Prepared by: Kate Palbom Michael G. Wilson, PhD Program Leads / Editors: Jean Bacon Sean B. Rourke, PhD Michael G. Wilson, PhD Contact:: rapidresponse@ohtn.on.ca panic disorder, social anxiety; and maladaptive coping in chronic medical conditions like cancer, and chronic pain. Most commonly used MBIs include mindfulness-based stress

2012 Ontario HIV Treatment Network

72. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study

monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 2011; 343:d6884 PubMedID Original Paper URL Other publications of related interest Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV and receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011:d6792. Indexing Status Subject indexing assigned by NLM MeSH Adult; Anti-Retroviral (...) Agents /economics /therapeutic use; CD4 Lymphocyte Count /economics; Cost-Benefit Analysis; Disability Evaluation; Female; HIV Infections /drug therapy /economics /epidemiology; Humans; Male; Quality-Adjusted Life Years; Uganda /epidemiology; Viral Load /economics AccessionNumber 22011001862 Date bibliographic record published 23/01/2012 Date abstract record published 17/03/2012 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University

2012 NHS Economic Evaluation Database.

73. The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation

Actual Study Completion Date : December 31, 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Early cessation Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum. Drug: Telbivudine 600mg Pregnant mothers who opted for antiviral (...) ? Will the proportion of postpartum flares be reduced if extending the duration of AVT after delivery? There is an urgent need in this area. This study mainly investigated the safety of antiviral therapy in preventing HBV mother-to-child transmission in pregnant women after discontinuation. Condition or disease Intervention/treatment Phase Hepatitis B, Chronic Drug: Telbivudine 600mg Drug: Tenofovir disoproxil fumarate 300mg Phase 4 Detailed Description: Between June 2015 and December 2017, 111 mothers were

2018 Clinical Trials

74. A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

) (HIV 1/2 antibodies), due to concerns for potential drug-drug interactions with entinostat and anti-retroviral medications. Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior (...) sperm donations for at least 120 days after the last dose of study drug. Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ≤ 2 (except alopecia and Grade 3 neuropathy). Exclusion Criteria (both phases): Subjects who have had chemotherapy, biological therapy, immunological therapy, radiation therapy, or hormonal therapy within 3 weeks prior to entering the study. Subjects who are unable or unwilling to discontinue use of prohibited medications. Subject

2018 Clinical Trials

75. Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

(Clinical Trial) Estimated Enrollment : 251 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) Actual Study Start Date : May 1, 2018 Estimated Primary Completion Date : April 2020 Estimated Study Completion Date : April 2021 Resource links provided by the National Library of Medicine related topics: available for: Arms (...) , PhD 81-952-34-3010 Korea, Republic of Hanyang University Seoul Hospital Recruiting Seoul, Korea, Republic of, 04736 Contact: Daewon Jun, MD, PhD 82-10-3259-7180 Nowon Eulji Medical Center, Eulji University College of Medicine, Recruiting Seoul, Korea, Republic of Contact: Sang Bong Ahn, MD, PhD Sanggye Paik Hospital, Inje University College of Medicine Recruiting Seoul, Korea, Republic of Contact: Eileen L. Yoon, MD, PhD Taiwan Kaohsiung Medical University Hospital Recruiting Kaohsiung, Taiwan

2018 Clinical Trials

76. Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

immunotherapeutic vaccine within 90 days of Screening. Treatment with any of the following agents within 28 days of Screening radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant. Treatment with any agent with documented activity against HIV-1 in vitro within 28 days of first dose of study treatment. Receipt of any prohibited medication and inability or unwillingness to switch to an alternative medication. Exposure to an experimental drug or experimental vaccine within either 28 (...) the efficacy and safety of DTG/3TC as a FDC, in ART-naive HIV-1-infected adolescents, who weigh at least 40 kilograms. The study will consists of Screening Phase (up to 28 days prior to the first dose of drug) followed by Treatment Phase (up to 48 weeks). Subjects who successfully complete 48 weeks of therapy and who continue to receive benefit from DTG/3TC FDC may enter a 96-week study Extension Phase. All subjects will receive the FDC of DTG/3TC (50/300 milligrams) for once daily. Approximately 30

2018 Clinical Trials

77. Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

and infants. Condition or disease Intervention/treatment Phase Hepatitis B Virus Infection Drug: Tenofovir Alafenamide Phase 4 Detailed Description: This is a multi-centered study conducted in 12-16 collaborative hospitals in Taiwan, using tenofovir as antiviral therapy to reduce mother-to-infant transmission. The study group recruited pregnant women at 2nd to 3rd trimester receive tenofovir disoproxil fumurate (TDF) 2011-2018, June, and receive tenofovir alafenamide (TAF) 2018-2021. Control group did (...) Actual Study Start Date : December 29, 2010 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December 31, 2021 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: treatment group Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum. Drug: Tenofovir Alafenamide Pregnant women receiving

2018 Clinical Trials

78. Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, AIDS-Related Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, B-Cell Lymphoma, Non-Hodgkin Methotrexate Anti-Retroviral Agents Abortifacient Agents, Nonsteroidal Abortifacient (...) System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy Actual Study Start Date : March 15, 2015 Actual Primary Completion Date : October 1, 2016 Actual Study Completion Date : October 1, 2016 Resource links provided by the National Library of Medicine related topics: available for: resources: Groups and Cohorts Go to Group/Cohort Intervention/treatment Cases Other: Retrospective survival analysis Kaplan-Meier model Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

79. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea Full Text available with Trip Pro

possible risk factors in patients on Highly Active Anti-retroviral Therapy (HAART). This is a case series assessment of spontaneously reported cases to the Eritrean Pharmacovigilance Centre. Data extracted from VigiFlow (reported between 2014 and 2016) were exported to excel spread sheet for descriptive and qualitative analysis. Naranjo probability scale and Austin Bradford-Hill criteria were used to assess causality. The P-Method was used to assess preventability. A total of 31 of cases (...) Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea WHO information note indicates that isoniazid preventive therapy (IPT) is generally safe with little risk of hepatotoxicity. However, when the policy of IPT for HIV patients was introduced in Eritrea, frequent IPT-associated hepatotoxicity and fatality have been reported to the Pharmacovigilance Centre. The aim of the study is to assess the causal association of IPT and hepatotoxicity and identify

2018 Pharmacology research & perspectives

80. Dietary diversity and associated factors among HIV positive adults attending antiretroviral therapy clinics at Hiwot Fana and Dilchora Hospitals, eastern Ethiopia Full Text available with Trip Pro

). Duration of anti-retroviral treatment was the factor significantly associated with dietary diversity: respondents with a duration of antiretroviral treatment of more than 2 years were almost two times more likely to have high dietary diversity compared with those with less than a year of antiretroviral treatment (adjusted odds ratio =0.490; 95% CI: 0.091, 0.978).Low dietary diversity was found to be a nutritional problem among HIV positive adults. Duration of antiretroviral treatment was the predictor (...) Dietary diversity and associated factors among HIV positive adults attending antiretroviral therapy clinics at Hiwot Fana and Dilchora Hospitals, eastern Ethiopia Nutritional care is considered a crucial component of comprehensive care for people living with HIV/AIDS (PLWHA), particularly in resource-limited settings where malnutrition and food insecurity are endemic problems, and low quality monotonous diets are the norm. The findings of this study provide baseline information on dietary

2018 HIV/AIDS (Auckland, N.Z.)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>